As of 2026-01-05, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is -1.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is 83.78 mil USD. SPRO's TTM EBITDA according to its financial statements is -44.99 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 15.2x | 13.8x |
| Forward P/E multiples | 15.9x - 21.9x | 18.9x |
| Fair Price | (11.83) - (11.27) | (12.19) |
| Upside | -603.5% - -579.8% | -618.8% |
| Date | EV/EBITDA |
| 2026-01-02 | -1.86 |
| 2025-12-31 | -1.84 |
| 2025-12-30 | -1.76 |
| 2025-12-29 | -1.80 |
| 2025-12-26 | -1.82 |
| 2025-12-24 | -1.85 |
| 2025-12-23 | -1.84 |
| 2025-12-22 | -1.89 |
| 2025-12-19 | -1.82 |
| 2025-12-18 | -1.79 |
| 2025-12-17 | -1.81 |
| 2025-12-16 | -1.76 |
| 2025-12-15 | -1.79 |
| 2025-12-12 | -1.82 |
| 2025-12-11 | -1.86 |
| 2025-12-10 | -1.84 |
| 2025-12-09 | -1.84 |
| 2025-12-08 | -1.81 |
| 2025-12-05 | -1.75 |
| 2025-12-04 | -1.77 |
| 2025-12-03 | -1.77 |
| 2025-12-02 | -1.67 |
| 2025-12-01 | -1.76 |
| 2025-11-28 | -1.92 |
| 2025-11-26 | -1.84 |
| 2025-11-25 | -1.85 |
| 2025-11-24 | -1.90 |
| 2025-11-21 | -1.81 |
| 2025-11-20 | -1.75 |
| 2025-11-19 | -1.90 |
| 2025-11-18 | -2.01 |
| 2025-11-17 | -1.96 |
| 2025-11-14 | -1.94 |
| 2025-11-13 | -1.98 |
| 2025-11-12 | -2.25 |
| 2025-11-11 | -2.20 |
| 2025-11-10 | -2.05 |
| 2025-11-07 | -2.00 |
| 2025-11-06 | -1.91 |
| 2025-11-05 | -1.96 |
| 2025-11-04 | -1.86 |
| 2025-11-03 | -1.90 |
| 2025-10-31 | -1.96 |
| 2025-10-30 | -1.87 |
| 2025-10-29 | -1.84 |
| 2025-10-28 | -1.90 |
| 2025-10-27 | -1.79 |
| 2025-10-24 | -1.69 |
| 2025-10-23 | -1.67 |
| 2025-10-22 | -1.74 |